RS-17053 2-CYCLOPROPYLMETHOXYPHENOXY)ETHYL]-5-CHLORO-ALPHA, ALPHA-DIMETHYL-1H-INDOLE-3-ETHANAMINE HYDROCHLORIDE), A SELECTIVE ALPHA(1A)-ADRENOCEPTOR ANTAGONIST, DISPLAYS LOW-AFFINITY FOR FUNCTIONAL ALPHA(1)-ADRENOCEPTORS IN HUMAN PROSTATE - IMPLICATIONS FOR ADRENOCEPTOR CLASSIFICATION

Citation
Apdw. Ford et al., RS-17053 2-CYCLOPROPYLMETHOXYPHENOXY)ETHYL]-5-CHLORO-ALPHA, ALPHA-DIMETHYL-1H-INDOLE-3-ETHANAMINE HYDROCHLORIDE), A SELECTIVE ALPHA(1A)-ADRENOCEPTOR ANTAGONIST, DISPLAYS LOW-AFFINITY FOR FUNCTIONAL ALPHA(1)-ADRENOCEPTORS IN HUMAN PROSTATE - IMPLICATIONS FOR ADRENOCEPTOR CLASSIFICATION, Molecular pharmacology, 49(2), 1996, pp. 209-215
Citations number
26
Categorie Soggetti
Pharmacology & Pharmacy",Biology
Journal title
ISSN journal
0026895X
Volume
49
Issue
2
Year of publication
1996
Pages
209 - 215
Database
ISI
SICI code
0026-895X(1996)49:2<209:R2A>2.0.ZU;2-F
Abstract
Norepinephrine (NE) contracts smooth muscle cells within the human low er urinary tract (LUT) (bladder neck, prostate, and urethra). Receptor distribution and pharmacological evidence have implicated activation of alpha(1A)-adrenoceptors. We disclose the pharmacological properties of the novel, selective alpha(1A)- adrenoceptor antagonist chloro-alp ha,alpha-dimethyl-1H-indole-3-ethanamine hydrochloride (RS-17053) and examine critically the pharmacological identity of the alpha(1)-adreno ceptor mediating contractions to NE in human LUT tissues. In several t issues from rat and cloned adrenoceptors, RS-17053 displayed high affi nity for the alpha(1A)-adrenoceptor (pK(i) and pA(2) estimates of 9.1- 9.9) and a 30-100-fold selectivity over the alpha(1B)- and the alpha(1 D)-adrenoceptor subtypes (pK(i) and pA(2) estimates of 7.7-7.8). Howev er, in isolated smooth muscle preparations from human LUT tissues, RS- 17053 antagonized responses to NE only at high concentrations. Estimat es of affinity (pA(2)) at alpha(1)-adrenoceptors mediating NE-induced contractions were 7.5 in prostatic periurethral longitudinal smooth mu scle (compared with 8.6 for prazosin), 6.9 in anterior fibromuscular s troma (prazosin, 8.9), and 7.1 in bladder neck (prazosin, 8.5). These findings indicate that contractile responses to NE in human LUT tissue s are mediated by a receptor displaying pharmacological properties tha t are clearly different from those of the defined alpha(1A)-adrenocept or ii and raise the possibility that multiple forms of the alpha(1A)-a drenoceptor may exist in human LUT that are discriminated by RS-17053. In this regard, the affinity estimates obtained with RS-17053 and oth er alpha(1)-adrenoceptor antagonists in human LUT tissues are identica l to those described for the putative alpha(1L)-adrenoceptor.